A phase II multicenter study of mycophenolate mofetil for acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation from related donors

Trial Profile

A phase II multicenter study of mycophenolate mofetil for acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation from related donors

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Ciclosporin
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2017 Results of two Japanese phase II studies including this study published in the International Journal of Hematology
    • 01 Apr 2017 Status changed from active, no longer recruiting to completed according to results published in the International Journal of Hematology.
    • 31 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top